Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrolizumab in Patients with Microsatellite-Stable, Metastatic Colorectal or Pancreatic Cancer
(WorldNews Netherlands)

Latest data from Phase 1/2 Study of NOX-A12 and pembrolizumab in patients with micro-satellite stable metastatic colorectal or pancreatic cancer ESMO 2019 Conference Poster 30 September 2019 Forward-looking Statements The information and opinions contained in this presentation and any other information discussed at this presentation are provided as at the date of this presentation and are therefore of a preliminary nature, have not been independently verified and may be subject to updating, revision, amendment or change without notice and in some cases has not been audited or reviewed by the Company`s auditors. This presentation is selective in nature and does not purport to contain all...